Craig I Coleman
YOU?
Author Swipe
View article: Coccidioidomycosis-Attributable Death in the United States: An Analysis of Cases Reported on Death Certificates, 2018–2023
Coccidioidomycosis-Attributable Death in the United States: An Analysis of Cases Reported on Death Certificates, 2018–2023 Open
Contemporary data on coccidioidomycosis death rates are sparse. Death certificate data for 2018–2023 from the US National Vital Statistics System were evaluated. Coccidioidomycosis deaths were identified using diagnosis codes B38.x listed …
View article: Healthcare Resource Utilization, Treatment Costs, and Mortality in Patients with Malignancies or Transplantation Who Develop Invasive Aspergillosis
Healthcare Resource Utilization, Treatment Costs, and Mortality in Patients with Malignancies or Transplantation Who Develop Invasive Aspergillosis Open
Objectives: Invasive aspergillosis (IA) poses significant risks to patients with malignancies or transplantation; however, estimates of burden-of-illness in patients with IA are sparse. We sought to assess in-hospital and outpatient health…
View article: Cost-effectiveness of olorofim in the treatment of invasive aspergillosis in patients with limited suitable alternative treatment options: a US payer perspective
Cost-effectiveness of olorofim in the treatment of invasive aspergillosis in patients with limited suitable alternative treatment options: a US payer perspective Open
This study aimed to estimate the cost-effectiveness of treating invasive aspergillosis (IA) in patients with limited treatment options with either olorofim or currently available antifungal salvage therapy from a US payer perspective. A hy…
View article: Effectiveness and Safety of Rivaroxaban Versus Warfarin in Venous Thromboembolism Patients with Comorbid Obstructive Sleep Apnea: A Retrospective Cohort Study
Effectiveness and Safety of Rivaroxaban Versus Warfarin in Venous Thromboembolism Patients with Comorbid Obstructive Sleep Apnea: A Retrospective Cohort Study Open
Introduction Obstructive sleep apnea (OSA) is prevalent in patients with venous thromboembolism (VTE). We sought to evaluate the effectiveness and safety of rivaroxaban versus warfarin in VTE patients with comorbid OSA. Methods We performe…
View article: Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease
Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease Open
View article: An External Control Arm for the Oral Factor XIa Inhibitor Asundexian Phase 2 Trial in Atrial Fibrillation (PACIFIC-AF) Using Electronic Health Records
An External Control Arm for the Oral Factor XIa Inhibitor Asundexian Phase 2 Trial in Atrial Fibrillation (PACIFIC-AF) Using Electronic Health Records Open
ECAs matching the PACIFIC-AF apixaban arm could be built from EHRs with concordant event rates for key trial endpoints. The ECA approach enabled the determination of event rates for treatment duration up to 2 years, thereby informing the a…
View article: Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study
Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study Open
View article: The Burden of Hospital Illness Associated with Disseminated Versus Isolated Pulmonary Coccidioidomycosis in the United States
The Burden of Hospital Illness Associated with Disseminated Versus Isolated Pulmonary Coccidioidomycosis in the United States Open
There are scarce data comparing inpatient mortality, length of stay (LOS) and all-cause hospital costs in disseminated coccidioidomycosis (DCM) vs. isolated pulmonary coccidioidomycosis (IPCM). We assessed the burden of hospital illness as…
View article: P-1010. Clinical and Economic Burden of Changing Initial Antifungal Regimens in Invasive Aspergillosis: A Hospital Perspective
P-1010. Clinical and Economic Burden of Changing Initial Antifungal Regimens in Invasive Aspergillosis: A Hospital Perspective Open
Background Initial antifungal (AF) regimens (AFR) for Invasive Aspergillosis (IA) are often changed due to treatment failure, intolerability, or drug-drug interactions. We compared outcomes among IA patients who did and did not change thei…
View article: P-1011. Real-World Antifungal Therapy Patterns in US Patients with Invasive Aspergillosis: It’s Complicated
P-1011. Real-World Antifungal Therapy Patterns in US Patients with Invasive Aspergillosis: It’s Complicated Open
Background The complexity of antifungal therapy (AFT) in Invasive Aspergillosis (IA) can complicate care. We sought to better understand AFT changes that occur in IA across both in- and outpatient settings of care.Table 1.Baseline Characte…
View article: P-911. Antifungal Treatment Patterns, Healthcare Utilization, Costs and Mortality in Coccidioidal Meningitis Patients: A Descriptive Analysis of United States Nationwide Claims Database
P-911. Antifungal Treatment Patterns, Healthcare Utilization, Costs and Mortality in Coccidioidal Meningitis Patients: A Descriptive Analysis of United States Nationwide Claims Database Open
Background Coccidioidal meningitis (CM) patients require lifelong antifungal therapy (AFT) to reduce morbidity and mortality. This study sought to identify CM patients and characterize their AFT patterns, healthcare utilization, costs, and…
View article: P-907. Burden of Hospitalization for Coccidioidal Meningitis: A National Cohort Study
P-907. Burden of Hospitalization for Coccidioidal Meningitis: A National Cohort Study Open
Background Coccidioidal meningitis (CM) is a severe complication of an endemic fungal infection requiring life-long aggressive medical and often surgical management necessitating hospitalization. Few data evaluating the burden of CM on hos…
View article: Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality
Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality Open
Delay in administering andexanet alfa due to hospital transfer may be associated with increased all-cause mortality.
View article: Association Between the Need to Change Initial Antifungal Therapy and Treatment Costs in Patients With Invasive Aspergillosis
Association Between the Need to Change Initial Antifungal Therapy and Treatment Costs in Patients With Invasive Aspergillosis Open
Background Early antifungal initiation in invasive aspergillosis (IA) is recommended. Changing antifungals occurs for a myriad of reasons but associated costs are unclear. Methods US claims data for adults admitted for IA were identified f…
View article: Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study
Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study Open
View article: Real-World Antifungal Therapy Patterns Across the Continuum of Care in United States Adults with Invasive Aspergillosis
Real-World Antifungal Therapy Patterns Across the Continuum of Care in United States Adults with Invasive Aspergillosis Open
Changes to antifungal therapy (AFT) in invasive aspergillosis (IA) may occur due to intolerance, side effects, drug interactions, or lack of response. We describe AFT change patterns in IA patients. This was a US claims data study. IA pati…
View article: Burden of Hospitalization for Coccidioidal Meningitis: An Analysis of the National Inpatient Sample, 2019–2021
Burden of Hospitalization for Coccidioidal Meningitis: An Analysis of the National Inpatient Sample, 2019–2021 Open
Coccidioidal meningitis (CM) requires lifelong aggressive management, often necessitating hospitalization. In the National Inpatient Sample (2019–2021), CM hospitalizations (N = 2305) were associated with frequent CM-related procedures (63…
View article: Management of factor Xa inhibitor–related traumatic non‐intracranial bleeding events with andexanet alfa or four‐factor prothrombin complex concentrate in a US multicenter observational study
Management of factor Xa inhibitor–related traumatic non‐intracranial bleeding events with andexanet alfa or four‐factor prothrombin complex concentrate in a US multicenter observational study Open
This analysis provides insights into the clinical characteristics and management strategies, including time to treatment, for patients treated with andexanet alfa or 4F-PCC while hospitalized for FXa inhibitor-related traumatic bleeds.
View article: Using 30-day modified rankin scale score to predict 90-day score in patients with intracranial hemorrhage: Derivation and validation of prediction model
Using 30-day modified rankin scale score to predict 90-day score in patients with intracranial hemorrhage: Derivation and validation of prediction model Open
Whether 30-day modified Rankin Scale (mRS) scores can predict 90-day scores is unclear. This study derived and validated a model to predict ordinal 90-day mRS score in an intracerebral hemorrhage (ICH) population using 30-day mRS values an…
View article: Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study
Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study Open
Background Treating cancer-associated venous thromboembolism (CAT) with anticoagulation prevents recurrent venous thromboembolism (rVTE), but increases bleeding risk. Objectives To compare incidence of rVTE, major bleeding, and all-cause m…
View article: Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta‐analysis
Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta‐analysis Open
Previous meta‐analyses assessed andexanet alfa (AA) or prothrombin complex concentrate (PCC) products for the treatment of Factor Xa inhibitor (FXaI)‐associated major bleeding. However, they did not include recent studies or assess the imp…
View article: Reply to “Letter to Dobesh et al. on lower mortality with andexanet alfa in factor Xa inhibitor–related major bleeding”
Reply to “Letter to Dobesh et al. on lower mortality with andexanet alfa in factor Xa inhibitor–related major bleeding” Open
View article: Agreement between 30-day and 90-day modified Rankin Scale score and utility-weighted modified Rankin Scale score in acute intracerebral hemorrhage: An analysis of ATACH-2 trial data
Agreement between 30-day and 90-day modified Rankin Scale score and utility-weighted modified Rankin Scale score in acute intracerebral hemorrhage: An analysis of ATACH-2 trial data Open
The relationship between 30- and 90-day modified Rankin Scale (mRS) scores in intracerebral hemorrhage (ICH) patients was evaluated. This post hoc cohort analysis of the ATACH-2 trial included patients with acute ICH who were alive at 30 d…
View article: Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study
Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study Open
Background In most patients with cancer-associated venous thromboembolism (CT), essentially those not at high risk of bleeding, guidelines recommend treatment with direct oral anticoagulants as an alternative to low-molecular-weight hepari…
View article: Rivaroxaban vs Vitamin K Antagonist in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease
Rivaroxaban vs Vitamin K Antagonist in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease Open
In patients with AF and advanced chronic kidney disease, those receiving rivaroxaban had less adverse kidney events and lower all-cause mortality compared to those receiving VKA, supporting the use of rivaroxaban in this high-risk group of…
View article: A meta-analysis of high-dose versus low-dose 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitor-associated intracerebral hemorrhage
A meta-analysis of high-dose versus low-dose 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitor-associated intracerebral hemorrhage Open
Background Four-factor prothrombin complex concentrate (4FPCC) are often used off-label for treating factor Xa inhibitor-associated major bleeding, including intracerebral hemorrhage (ICH). In addition to debate over 4FPCC’s effectiveness …
View article: Effectiveness of high- versus low-dose four-factor prothrombin complex concentrate on hemostasis and thromboembolism in patients with oral factor Xa inhibitor-associated intracranial hemorrhage
Effectiveness of high- versus low-dose four-factor prothrombin complex concentrate on hemostasis and thromboembolism in patients with oral factor Xa inhibitor-associated intracranial hemorrhage Open
Background Four-factor prothrombin complex concentrate (4F-PCC) is frequently used off-label for the reversal of oral factor Xa inhibitor-associated bleeding. Dosing of 4F-PCC in routine practice remains inconsistent as published observati…
View article: OC 31.2 Andexanet Alfa is Associated with Lower In-Hospital Mortality Compared to 4-Factor Prothrombin Complex Concentrate in Patients with Factor Xa Inhibitor–Related Major Bleeding
OC 31.2 Andexanet Alfa is Associated with Lower In-Hospital Mortality Compared to 4-Factor Prothrombin Complex Concentrate in Patients with Factor Xa Inhibitor–Related Major Bleeding Open
View article: PB1110 Implementation of International Society on Thrombosis and Haemostasis Definitions of Major and Clinically Relevant Non-Major Bleed Events in Electronic Health Records
PB1110 Implementation of International Society on Thrombosis and Haemostasis Definitions of Major and Clinically Relevant Non-Major Bleed Events in Electronic Health Records Open
View article: OC 54.1 Effectiveness and Safety of Rivaroxaban and Low Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism: A Meta-Analysis of Oscar Programme Findings
OC 54.1 Effectiveness and Safety of Rivaroxaban and Low Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism: A Meta-Analysis of Oscar Programme Findings Open